← Eichor
Condition: Carcinoma Of Unknown Primary Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Carcinoma Of Unknown Primary

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06995508Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05172245Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Phase N/A · 1 location(s) · Regina Elena Cancer Institute · NCT05918510A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraopera
Phase 2 · 1 location(s) · University of Texas Southwestern Medical Center · NCT05576974TCF-001 TRACK (Target Rare Cancer Knowledge) Study
NA · 1 location(s) · TargetCancer Foundation · NCT04504604Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT04754321Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spre
Phase 3 · 192 location(s) · National Cancer Institute (NCI) · NCT06589804Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05544136Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown
Phase 2 · 6 location(s) · Centre Hospitalier Universitaire Dijon · NCT04325425Genomic Investigation of Unusual Responders
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03740503TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058Cancer Genetic Testing in Ethnic Populations
NA · 2 location(s) · Mayo Clinic · NCT04475640Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastati
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT03010150Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head
Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT07217028Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NA · 344 location(s) · Alliance for Clinical Trials in Oncology · NCT07283939[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
NA · 6 location(s) · Erasmus Medical Center · NCT06644716Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab
Phase 2 · 19 location(s) · Grupo Espanol de Tumores Neuroendocrinos · NCT07061080
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.